Developer docs
API playgroundTry for free, no card

Search company profiles

Mediar Therapeutics

Full company profile

uuid0000bau

Namestring
Mediar Therapeutics
Legal namestring
Mediar Therapeutics, Inc.
Websiteurl
mediartx.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Mediar Therapeutics is a clinical-stage biotechnology company founded in 2019 as a spinout of Massachusetts General Hospital and Brigham and Women's Hospital (Mass General Brigham), based in Boston, Massachusetts. The company develops first-in-class human IgG1 monoclonal antibodies designed to disable the myofibroblast — the pathogenic cell that drives collagen deposition, extracellular matrix accumulation, and progressive organ scarring in fibrosis — by targeting novel fibrotic mediators WISP1, EphrinB2, and SMOC2. Its clinical pipeline comprises MTX-463 (anti-WISP1, Phase 2 WISPer trial in idiopathic pulmonary fibrosis), MTX-474 (anti-EphrinB2, Phase 2 EncompaSSc trial in diffuse cutaneous systemic sclerosis), and MTX-439 (anti-SMOC2, Phase 1 in chronic kidney disease), plus a portfolio of bi-specific antibody programs in lead optimization in oncology and inflammatory bowel disease.

The company's business model is B2B/partnership-driven: Mediar generates revenue exclusively through out-licensing clinical-stage assets to large pharmaceutical partners rather than direct product sales, exemplified by a January 2025 global licensing agreement with Eli Lilly for MTX-463 that provides $99M in upfront and near-term milestone payments, up to $687M in development and commercialization milestones, and high-single to low-double-digit tiered royalties on future net sales. Pre-commercial operations are funded through venture capital, with approximately $181M+ raised across a 2021 seed round led by Pfizer Ventures, a March 2023 $85M Series A co-led by Novartis Venture Fund and Sofinnova Partners, and a January 2026 oversubscribed $76M Series B co-led by Amplitude Ventures and ICG. Mediar also runs investigator-sponsored and company-sponsored clinical trials globally and relies on specialized discovery (Alloy Therapeutics) and imaging analytics (Qureight) partnerships to accelerate and de-risk its pipeline. Approximately 40+ team members operate across antibody engineering, clinical operations, regulatory, quality, biostatistics, translational medicine, CMC, and data management functions under a leadership team whose fibrosis experience includes prior senior roles at Pfizer, Gilead, Biogen, and Takeda.

Short descriptiontext

Mediar Therapeutics is a clinical-stage biotechnology company developing first-in-class monoclonal antibodies that target the myofibroblast to halt and reverse fibrosis, with three clinical programs in IPF, systemic sclerosis, and chronic kidney disease, and a global licensing partnership with Eli Lilly for its lead asset.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
fibrosis therapeutics, monoclonal antibody therapy, anti-fibrotic drugs, clinical-stage biotechnology, biopharmaceutical R&D
Industry2 codes
PRIMARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Out-licensing of clinical-stage assets
TypeLicensing Royalties
Description

Generates revenue via global licensing deals with large pharmaceutical partners. Eli Lilly deal for MTX-463 (anti-WISP1) provides $99M in upfront and near-term milestone payments, up to $687M in additional development and commercialization milestones, plus high-single to low-double-digit tiered royalties on future net sales. Deal is back-weighted on milestones.

mediartx.com
2Private equity financing (pre-commercial)
TypeLicensing Royalties
Description

Clinical-stage biotech currently pre-revenue on product sales; capital is raised via venture financing rounds. Has raised $105M (Series A $85M co-led by Novartis Venture Fund and Sofinnova Partners in 2023, plus prior $20M seed) and an oversubscribed $76M Series B in January 2026 co-led by Amplitude Ventures and ICG.

mediartx.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Mediar Therapeutics is a clinical-stage biotechnology company developing first-in-class monoclonal antibody therapeutics that target the myofibroblast — the key pathogenic cell driving fibrosis — to halt and reverse scarring in fibrotic diseases. The pipeline includes three clinical-stage programs: MTX-463 (anti-WISP1) in Phase 2 for idiopathic pulmonary fibrosis (IPF), MTX-474 (anti-EphrinB2) in Phase 2 for diffuse cutaneous systemic sclerosis (SSc), and MTX-439 (anti-SMOC2) in Phase 1 for chronic kidney disease (CKD), plus bi-specific antibody programs in lead optimization for oncology and IBD indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • $99M in upfront and near-term milestone payments from Eli Lilly plus up to $687M in development/commercialization milestones and tiered royalties for global rights to MTX-463
+3 more records
Product overview1 text field

No product/service information was available in the provided source data.

Product and service4 records
1MTX-463 (anti-WISP1 antibody)
CategoryAnti-fibrotic monoclonal antibody therapeutic
Description

MTX-463 is a first-in-class human IgG1 monoclonal antibody designed to neutralize WISP1-mediated fibrotic signaling, with activity spanning lung and liver fibrosis indications. It is currently in Phase 2 development for idiopathic pulmonary fibrosis (IPF) under a global licensing partnership with Eli Lilly.

2MTX-474 (anti-EphrinB2 antibody)
CategoryAnti-fibrotic monoclonal antibody therapeutic
Description

MTX-474 is a first-in-class human IgG1 monoclonal antibody designed to neutralize EphrinB2 signaling that drives myofibroblast activation, tissue remodeling and fibrosis of skin, lungs and heart. It is currently in Phase 2 development for diffuse cutaneous Systemic Sclerosis (SSc) under the EncompaSSc clinical trial.

3MTX-439 (anti-SMOC2 antibody)
CategoryAnti-fibrotic monoclonal antibody therapeutic
Description

MTX-439 is a first-in-class anti-SMOC2 antibody targeting a secreted matricellular protein that promotes extracellular matrix assembly, cell adhesion and kidney fibrosis. It is currently in Phase 1 development for chronic kidney disease (CKD), including diabetic kidney disease.

4Bi-specific antibody programs
CategoryAnti-fibrotic bi-specific antibody therapeutic
Description

Pipeline of novel bi-specific antibodies in lead optimization designed to further unlock validated anti-fibrotic mechanisms; currently advancing two bi-specific programs in Oncology and IBD indications.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-05-13
Description

Qureight is an imaging CRO supporting Mediar's Phase 2 EncompaSSc clinical trial of MTX-474 in diffuse cutaneous Systemic Sclerosis. Qureight provides its AI-powered 3D quantitative imaging analytics platform — including Glass8, Fibr8, Vascul8, Air8, and Lung8 models — to analyze HRCT lung images from trial participants at screening and at 24 weeks following treatment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-02
Description

Antibody discovery collaboration leveraging Alloy's ATX-Gx human transgenic mouse platform, genetic immunization strategies, and AI/ML-enabled discovery workflows. Delivered differentiated binders against challenging fibrosis targets, accelerating Mediar's development timeline by approximately six months and enabling multiple programs to enter clinical development ahead of schedule. The collaboration informed Mediar's lead program MTX-463, now in Phase 2 for IPF. Alloy supports 200+ partners globally across more than 100 active drug programs.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-01-10
Description

Global licensing agreement (announced January 10, 2025) granting Eli Lilly worldwide development and commercialization rights to Mediar's anti-WISP1 antibody MTX-463 for idiopathic pulmonary fibrosis (IPF). Deal includes $99M in upfront and near-term milestone payments, up to $687M in additional development and commercialization milestones, plus high-single to low-double-digit tiered royalties on future net sales. First patient was dosed in the Phase 2 WISPer trial in June 2025 under this partnership.

Strategic tierMinorTypeOthers
Description

Listed on Mediar's investor page; a life sciences-focused real estate investment trust (REIT) that develops and leases lab space to biotech tenants.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Mediar was founded in 2019 as a spinout from Massachusetts General Hospital and Brigham and Women's Hospital (Mass General Brigham) based on fibrosis research from those institutions' labs. Co-founders include researchers whose work on the myofibroblast and targets such as EphrinB2 (Nature Medicine 2017) and SMOC2 (JCI Insight 2017) underpins Mediar's pipeline.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing integrin-targeted therapeutics for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Directly comparable to Mediar as a fibrosis-focused biotech with programs in IPF and adjacent fibrotic indications.

2Blade Therapeutics
TypeDirect peer
Description

Clinical-stage company developing anti-fibrotic therapies for IPF and other fibrotic diseases, including a Phase 2 program in IPF. Closely aligned with Mediar in indication focus and fibrosis-modality strategy.

TypeDirect peer
Description

Clinical-stage fibrosis company with a lead IPF program (talotrexin/ENV-101). Same indication and similar clinical-stage positioning as Mediar's MTX-463, competing for the same IPF patient population and partnership interest.

TypeDirect peer
Description

Clinical-stage biotech developing inhaled therapies for IPF and progressive pulmonary fibrosis. Direct competitor in IPF, addressing the same patients Mediar is recruiting for in the WISPer trial.

TypeBroad incumbent
Description

Established public biotech with approved roxadustat and a broader pipeline including IPF (pamrevlumab). Comparable as a fibrosis-focused company with both clinical assets and a track record of large pharma partnerships.

6Boehringer Ingelheim (nintedanib/Ofev)
TypeBroad incumbent
Description

Markets nintedanib (Ofev), the standard-of-care anti-fibrotic for IPF. Represents the incumbent that any new IPF therapy (including Mediar's MTX-463) must displace or combine with.

TypeBroad incumbent
Description

Commercial-stage pulmonary company with treprostinil and a growing portfolio in pulmonary hypertension and IPF (Tyvaso DPI). Comparable as a larger pulmonary fibrosis player with both commercial and clinical assets.

TypeBroad incumbent
Description

Major pharma with active IPF and systemic sclerosis programs (e.g., Roche's idiopathic pulmonary fibrosis research and the legacy pirfenidone franchise through legacy partnerships). Likely counterpart for future out-licensing transactions from Mediar.

9Morphic Holding
TypeEmerging player
Description

Clinical-stage biotech developing oral integrin inhibitors for fibrotic diseases including IPF. Emerging overlap with Mediar in mechanism (integrins vs myofibroblast) and indication space.

TypeBroad incumbent
Description

Major pharma with fibrosis and immunology franchise and active IPF/SSc research. Likely licensor or competitor in the fibrosis space where Mediar is positioning its pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mediar Therapeutics

Biopharmaceuticalsmediartx.com

Mediar Therapeutics is a clinical-stage biotechnology company developing first-in-class monoclonal antibodies that target the myofibroblast to halt and reverse fibrosis, with three clinical programs in IPF, systemic sclerosis, and chronic kidney disease, and a global licensing partnership with Eli Lilly for its lead asset.

What Mediar Therapeutics does

Mediar Therapeutics is a clinical-stage biotechnology company founded in 2019 as a spinout of Massachusetts General Hospital and Brigham and Women's Hospital (Mass General Brigham), based in Boston, Massachusetts. The company develops first-in-class human IgG1 monoclonal antibodies designed to disable the myofibroblast — the pathogenic cell that drives collagen deposition, extracellular matrix accumulation, and progressive organ scarring in fibrosis — by targeting novel fibrotic mediators WISP1, EphrinB2, and SMOC2. Its clinical pipeline comprises MTX-463 (anti-WISP1, Phase 2 WISPer trial in idiopathic pulmonary fibrosis), MTX-474 (anti-EphrinB2, Phase 2 EncompaSSc trial in diffuse cutaneous systemic sclerosis), and MTX-439 (anti-SMOC2, Phase 1 in chronic kidney disease), plus a portfolio of bi-specific antibody programs in lead optimization in oncology and inflammatory bowel disease.

The company's business model is B2B/partnership-driven: Mediar generates revenue exclusively through out-licensing clinical-stage assets to large pharmaceutical partners rather than direct product sales, exemplified by a January 2025 global licensing agreement with Eli Lilly for MTX-463 that provides $99M in upfront and near-term milestone payments, up to $687M in development and commercialization milestones, and high-single to low-double-digit tiered royalties on future net sales. Pre-commercial operations are funded through venture capital, with approximately $181M+ raised across a 2021 seed round led by Pfizer Ventures, a March 2023 $85M Series A co-led by Novartis Venture Fund and Sofinnova Partners, and a January 2026 oversubscribed $76M Series B co-led by Amplitude Ventures and ICG. Mediar also runs investigator-sponsored and company-sponsored clinical trials globally and relies on specialized discovery (Alloy Therapeutics) and imaging analytics (Qureight) partnerships to accelerate and de-risk its pipeline. Approximately 40+ team members operate across antibody engineering, clinical operations, regulatory, quality, biostatistics, translational medicine, CMC, and data management functions under a leadership team whose fibrosis experience includes prior senior roles at Pfizer, Gilead, Biogen, and Takeda.

Mediar Therapeutics firmographics

Firmographics
Name
Mediar Therapeutics
Legal name
Mediar Therapeutics, Inc.
Website
https://mediartx.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
Mediar Therapeutics is a clinical-stage biotechnology company developing first-in-class monoclonal antibodies that target the myofibroblast to halt and reverse fibrosis, with three clinical programs in IPF, systemic sclerosis, and chronic kidney disease, and a global licensing partnership with Eli Lilly for its lead asset.
Ownership category
akta.pro rank

Mediar Therapeutics industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Fibrosis therapeutics
  • Monoclonal antibody therapy
  • Anti-fibrotic drugs
  • Clinical-stage biotechnology
  • Biopharmaceutical R&D

Where Mediar Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Mediar Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Out-licensing of clinical-stage assets: Generates revenue via global licensing deals with large pharmaceutical partners. Eli Lilly deal for MTX-463 (anti-WISP1) provides $99M in upfront and near-term milestone payments, up to $687M in additional development and commercialization milestones, plus high-single to low-double-digit tiered royalties on future net sales. Deal is back-weighted on milestones.
  2. Private equity financing (pre-commercial): Clinical-stage biotech currently pre-revenue on product sales; capital is raised via venture financing rounds. Has raised $105M (Series A $85M co-led by Novartis Venture Fund and Sofinnova Partners in 2023, plus prior $20M seed) and an oversubscribed $76M Series B in January 2026 co-led by Amplitude Ventures and ICG.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels7 records

Mediar Therapeutics product offering

Product offering

Core offering

Mediar Therapeutics is a clinical-stage biotechnology company developing first-in-class monoclonal antibody therapeutics that target the myofibroblast — the key pathogenic cell driving fibrosis — to halt and reverse scarring in fibrotic diseases. The pipeline includes three clinical-stage programs: MTX-463 (anti-WISP1) in Phase 2 for idiopathic pulmonary fibrosis (IPF), MTX-474 (anti-EphrinB2) in Phase 2 for diffuse cutaneous systemic sclerosis (SSc), and MTX-439 (anti-SMOC2) in Phase 1 for chronic kidney disease (CKD), plus bi-specific antibody programs in lead optimization for oncology and IBD indications.

Product overview

No product/service information was available in the provided source data.

Differentiator

Problem solved

Functional benefit

Products and services

  • MTX-463 (anti-WISP1 antibody) MTX-463 is a first-in-class human IgG1 monoclonal antibody designed to neutralize WISP1-mediated fibrotic signaling, with activity spanning lung and liver fibrosis indications. It is currently in Phase 2 development for idiopathic pulmonary fibrosis (IPF) under a global licensing partnership with Eli Lilly.
  • MTX-474 (anti-EphrinB2 antibody) MTX-474 is a first-in-class human IgG1 monoclonal antibody designed to neutralize EphrinB2 signaling that drives myofibroblast activation, tissue remodeling and fibrosis of skin, lungs and heart. It is currently in Phase 2 development for diffuse cutaneous Systemic Sclerosis (SSc) under the EncompaSSc clinical trial.
  • MTX-439 (anti-SMOC2 antibody) MTX-439 is a first-in-class anti-SMOC2 antibody targeting a secreted matricellular protein that promotes extracellular matrix assembly, cell adhesion and kidney fibrosis. It is currently in Phase 1 development for chronic kidney disease (CKD), including diabetic kidney disease.
  • Bi-specific antibody programs Pipeline of novel bi-specific antibodies in lead optimization designed to further unlock validated anti-fibrotic mechanisms; currently advancing two bi-specific programs in Oncology and IBD indications.

Quantifiable outcome

  • $99M in upfront and near-term milestone payments from Eli Lilly plus up to $687M in development/commercialization milestones and tiered royalties for global rights to MTX-463
  • +3 more outcomes

Companies that use Mediar Therapeutics

Customer profile

Segments5 records

Ideal customer profiles3 records

Mediar Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Mediar Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core, flagship and minor.

  • QureightcoreImplementation/ SI/ Consulting Partner · 13 May 2026Qureight is an imaging CRO supporting Mediar's Phase 2 EncompaSSc clinical trial of MTX-474 in diffuse cutaneous Systemic Sclerosis. Qureight provides its AI-powered 3D quantitative imaging analytics platform — including Glass8, Fibr8, Vascul8, Air8, and Lung8 models — to analyze HRCT lung images from trial participants at screening and at 24 weeks following treatment.
  • Alloy TherapeuticscoreStrategic or Co-development Partner · 2 February 2026Antibody discovery collaboration leveraging Alloy's ATX-Gx human transgenic mouse platform, genetic immunization strategies, and AI/ML-enabled discovery workflows. Delivered differentiated binders against challenging fibrosis targets, accelerating Mediar's development timeline by approximately six months and enabling multiple programs to enter clinical development ahead of schedule. The collaboration informed Mediar's lead program MTX-463, now in Phase 2 for IPF. Alloy supports 200+ partners globally across more than 100 active drug programs.
  • Eli Lilly and CompanyflagshipOEM/ Whitelabel/ Licensing Partner · 10 January 2025Global licensing agreement (announced January 10, 2025) granting Eli Lilly worldwide development and commercialization rights to Mediar's anti-WISP1 antibody MTX-463 for idiopathic pulmonary fibrosis (IPF). Deal includes $99M in upfront and near-term milestone payments, up to $687M in additional development and commercialization milestones, plus high-single to low-double-digit tiered royalties on future net sales. First patient was dosed in the Phase 2 WISPer trial in June 2025 under this partnership.
  • Alexandria Real Estate EquitiesminorOthersListed on Mediar's investor page; a life sciences-focused real estate investment trust (REIT) that develops and leases lab space to biotech tenants.
  • Mass General Brigham (founding institution)coreStrategic or Co-development PartnerMediar was founded in 2019 as a spinout from Massachusetts General Hospital and Brigham and Women's Hospital (Mass General Brigham) based on fibrosis research from those institutions' labs. Co-founders include researchers whose work on the myofibroblast and targets such as EphrinB2 (Nature Medicine 2017) and SMOC2 (JCI Insight 2017) underpins Mediar's pipeline.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Mediar Therapeutics competitors and assessment

Company assessment

Direct peers

  • Pliant Therapeutics: Clinical-stage biotech developing integrin-targeted therapeutics for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Directly comparable to Mediar as a fibrosis-focused biotech with programs in IPF and adjacent fibrotic indications.
  • Blade Therapeutics: Clinical-stage company developing anti-fibrotic therapies for IPF and other fibrotic diseases, including a Phase 2 program in IPF. Closely aligned with Mediar in indication focus and fibrosis-modality strategy.
  • Endeavor BioMedicines: Clinical-stage fibrosis company with a lead IPF program (talotrexin/ENV-101). Same indication and similar clinical-stage positioning as Mediar's MTX-463, competing for the same IPF patient population and partnership interest.
  • Avalyn Pharma: Clinical-stage biotech developing inhaled therapies for IPF and progressive pulmonary fibrosis. Direct competitor in IPF, addressing the same patients Mediar is recruiting for in the WISPer trial.

Broad incumbents

  • FibroGen: Established public biotech with approved roxadustat and a broader pipeline including IPF (pamrevlumab). Comparable as a fibrosis-focused company with both clinical assets and a track record of large pharma partnerships.
  • Boehringer Ingelheim (nintedanib/Ofev): Markets nintedanib (Ofev), the standard-of-care anti-fibrotic for IPF. Represents the incumbent that any new IPF therapy (including Mediar's MTX-463) must displace or combine with.
  • United Therapeutics: Commercial-stage pulmonary company with treprostinil and a growing portfolio in pulmonary hypertension and IPF (Tyvaso DPI). Comparable as a larger pulmonary fibrosis player with both commercial and clinical assets.
  • Roche / Genentech: Major pharma with active IPF and systemic sclerosis programs (e.g., Roche's idiopathic pulmonary fibrosis research and the legacy pirfenidone franchise through legacy partnerships). Likely counterpart for future out-licensing transactions from Mediar.
  • AbbVie (IPF program / telisotuzumab): Major pharma with fibrosis and immunology franchise and active IPF/SSc research. Likely licensor or competitor in the fibrosis space where Mediar is positioning its pipeline.

Emerging players

  • Morphic Holding: Clinical-stage biotech developing oral integrin inhibitors for fibrotic diseases including IPF. Emerging overlap with Mediar in mechanism (integrins vs myofibroblast) and indication space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Mediar Therapeutics social profiles

Digital presence

Mediar Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mediar Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Mediar Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mediar Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mediar Therapeutics

What does Mediar Therapeutics do?

Mediar Therapeutics is a clinical-stage biotechnology company developing first-in-class monoclonal antibody therapeutics that target the myofibroblast — the key pathogenic cell driving fibrosis — to halt and reverse scarring in fibrotic diseases. The pipeline includes three clinical-stage programs: MTX-463 (anti-WISP1) in Phase 2 for idiopathic pulmonary fibrosis (IPF), MTX-474 (anti-EphrinB2) in Phase 2 for diffuse cutaneous systemic sclerosis (SSc), and MTX-439 (anti-SMOC2) in Phase 1 for chronic kidney disease (CKD), plus bi-specific antibody programs in lead optimization for oncology and IBD indications.

Is Mediar Therapeutics a public or private company?

Mediar Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mediar Therapeutics founded?

Mediar Therapeutics was founded in 2019. It employs 51 to 100 people.

Where is Mediar Therapeutics based?

Mediar Therapeutics is headquartered in Boston, United States, in the North America region.

How does Mediar Therapeutics make money?

Two revenue lines are on record. Out-licensing of clinical-stage assets are the primary driver. The others are private equity financing (pre-commercial).

Who are Mediar Therapeutics's main competitors?

Direct peers on record are Pliant Therapeutics, Blade Therapeutics, Endeavor BioMedicines and Avalyn Pharma. Broad incumbents are FibroGen, Boehringer Ingelheim (nintedanib/Ofev), United Therapeutics, Roche / Genentech and AbbVie (IPF program / telisotuzumab). Morphic Holding is listed as an emerging player.

Does Mediar Therapeutics have an API?

No public API is recorded for Mediar Therapeutics.

What industry is Mediar Therapeutics in?

Mediar Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies, with a secondary code of HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireMediar Therapeutics Completes Enrollment in Phase 2 WISPer Trial of MTX-463 in Idiopathic Pulmonary Fibrosis (IPF)Mediar Therapeutics completed enrollment in its Phase 2 WISPer trial of MTX-463 for idiopathic pulmonary fibrosis, enrolling 168 patients across 70+ sites. The randomized, double-blind study tests the antibody's safety and efficacy, with the primary endpoint being change in forced vital capacity at Week 24. The trial is conducted under a global licensing agreement with Eli Lilly.BioSpacePharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic SclerosisPharmaNest and Mediar Therapeutics announced a collaboration to apply AI-enabled digital pathology to skin biopsies in the EncompaSSc Phase 2 trial of MTX-474 for diffuse cutaneous systemic sclerosis. The trial evaluates the antibody's safety and efficacy, with the primary endpoint being change in modified Rodnan Skin Score at week 24. The collaboration aims to quantify fibrosis and ECM remodeling at the single-fiber level.FinanzNachrichten.dePharmaNest und Mediar Therapeutics arbeiten gemeinsam an der Quantifizierung der ECM- und Fibrose-Remodellierung in der EncompaSSc-Phase-2-Studie zu MTX-474 bei diffuser kutaner systemischer SklerosePharmaNest and Mediar Therapeutics announced a collaboration to integrate AI-based digital pathology into the EncompaSSc Phase-2 study of MTX-474 for diffuse cutaneous systemic sclerosis. The partnership will use FibroNest to quantify ECM and fibrosis remodeling on skin biopsies, complementing the study's primary endpoint of mRSS change at week 24.AktienPharmaNest und Mediar Therapeutics arbeiten gemeinsam an der Quantifizierung der ECM- und Fibrose-Remodellierung in der EncompaSSc-Phase-2-Studie zu MTX-474 bei diffuser kutaner systemischer SklerosePharmaNest and Mediar Therapeutics announced a collaboration to integrate AI-based digital pathology into the EncompaSSc Phase-2 study of MTX-474 for diffuse cutaneous systemic sclerosis. The partnership will use FibroNest to quantify ECM and fibrosis remodeling on skin biopsies, complementing the study's primary endpoint of mRSS change at week 24.Pharmaceutical TechnologyMediar and Ono to develop fibro-inflammatory treatmentsMediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases, which cause organ failure through myofibroblast activation, scarring, and tissue inflammation. Under the agreement, Ono gains exclusive option to license worldwide rights to develop and commercialize Mediar's therapeutic programs, will provide an upfront payment, and support research and development costs. Mediar will continue advancing its own fibrosis pipeline including MTX-474 (Phase II for systemic sclerosis), MTX-463 (partnered with Eli Lilly for idiopathic pulmonary fibrosis), and MTX-439 (Phase I for chronic kidney disease-mediated fibrosis).The Pharma LetterMediar Therapeutics enters option deal with Ono PharmaMediar Therapeutics has entered into a collaboration and option agreement with Japan’s Ono Pharmaceutical for developing treatments for fibro-inflammatory diseases. These diseases involve tissue scarring, inflammation, and the risk of organ failure. The deal indicates strategic cooperation between the two biotech companies.YahooMediar Therapeutics Enters into a Collaboration and Option Agreement with Ono Pharma to Develop Novel Treatments for Fibro-inflammatory DiseasesMediar Therapeutics, a clinical-stage biotechnology company, has entered into a collaboration and option agreement with Ono Pharmaceutical Co., Ltd. for the development of novel antibody therapeutics targeting fibro-inflammatory diseases. Under the terms, Ono receives an exclusive option to license worldwide rights to develop and commercialize the programs, with Ono making an upfront payment and supporting R&D costs. Mediar will leverage its fibrosis-focused discovery platform and myofibroblast expertise while continuing to advance its own portfolio of first-in-class programs including MTX-474, MTX-463, and MTX-439.PR NewswireMediar Therapeutics Enters into a Collaboration and Option Agreement with Ono Pharma to Develop Novel Treatments for Fibro-inflammatory DiseasesMediar Therapeutics, a clinical-stage biotechnology company focused on fibrosis therapies, has entered into a collaboration and option agreement with Ono Pharmaceutical to develop novel antibody therapeutics targeting fibro-inflammatory diseases. Under the terms, Ono receives an exclusive option to license worldwide development and commercialization rights, making an upfront payment to Mediar while covering R&D costs. Mediar will continue advancing its independent pipeline including MTX-474 (Phase 2 for systemic sclerosis), MTX-463 (Phase 2 for idiopathic pulmonary fibrosis in partnership with Eli Lilly), and MTX-439 (Phase 1 for chronic kidney disease-mediated fibrosis).BioSpaceOno Pharma Enters into a Drug Discovery Partnership with Mediar Therapeutics to Create Novel Antibody Therapeutics for Fibro-inflammatory DiseasesOno Pharmaceutical entered a drug discovery partnership with Mediar Therapeutics to create antibody therapeutics for fibro-inflammatory diseases. Ono will have exclusive worldwide option rights to develop, manufacture, and commercialize candidates. The collaboration aims to accelerate biologics innovation in areas with high unmet medical need.Business Wire BlogOno Pharma Enters into a Drug Discovery Partnership with Mediar Therapeutics to Create Novel Antibody Therapeutics for Fibro-inflammatory DiseasesOno Pharmaceutical Co., Ltd. has entered into a drug discovery partnership and option agreement with Mediar Therapeutics, Inc., a clinical-stage biotechnology company, to create novel antibody therapeutics for fibro-inflammatory diseases. Mediar will conduct research leveraging its antibody discovery capabilities and fibrosis-focused research platform, while Ono receives exclusive worldwide option rights to select candidates for further development, manufacturing, and commercialization. Ono Venture Investment had previously participated as an investor in Mediar's seed extension financing round in March 2021, having built a collaborative relationship with the company prior to this partnership.